Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The angiotensin II type 2 receptor in cardiovascular disease

Open access
Lemarié, Catherine A, Schiffrin, Ernesto L·2010·Journal of the Renin-Angiotensin-Aldosterone System

Abstract

Angiotensin II (Ang II) is considered the major final mediator of the renin-angiotensin system. The actions of Ang II have been implicated in many cardiovascular conditions, such as hypertension, atherosclerosis, coronary heart disease, restenosis, and heart failure. Ang II can act through two different receptors: Ang II type 1 (AT 1) receptor and Ang II type 2 (AT 2) receptor. The AT 1 receptor is ubiquitously expressed in the cardiovascular system and mediates most of the physiological and pathophysiological actions of Ang II. The AT 2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT 2 receptor can be modulated by pathological states associated with tissue remodelling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. The precise role of the AT 2 receptor remains under debate. However, it appears that the AT 2 receptor plays a vasodilatory role, and may be enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis. Signalling pathways induced by the stimulation of the AT 2 receptor are poorly understood, but three main mechanisms have been described: (a) activation of protein phosphatases causing protein dephosphorylation; (b) activation of bradykinin/nitric oxide/cyclic guanosine 3’,5’-monophosphate pathway; and (c) stimulation of phospholipase A 2 and release of arachidonic acid. Vasodilatory effects of the AT 2 receptor, probably the only well-established role of the AT 2 receptor, have been attributed to the second of these mechanisms. The participation of the AT 2 receptor in cardiovascular remodelling and inflammation is more controversial. In vitro, AT 2 receptor stimulation clearly inhibits cardiac and vascular smooth muscle growth and proliferation, and stimulates apoptosis. In vivo, the situation is less clear, and depending on the studies, the AT 2 receptor appears to be required for cardiac hypertrophic growth or contrariwise, the AT 2 receptor has demonstrated no effects on cardiac hypertrophy. Similar controversial findings have been reported in atherosclerosis. Here we discuss the role of the AT 2 receptor on cardiovascular structure and disease, and the signalling pathways induced by its activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1470320309347785

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 179

Metadata

Authors
Lemarié, C. A., & Schiffrin, E. L.
Venue
Journal of the Renin-Angiotensin-Aldosterone System
Published
2009-10-27
Volume
11
Issue
1
Pages
19-31
ISSN
  • 1470-3203 (ISSN-L)
  • 1752-8976
OpenAlex
W2144030911
Cited by
179
References
2
FWCI
7.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The angiotensin II type 2 receptor in cardiovascular disease. https://app.cochat.ai/papers/10.1177/1470320309347785
The paper
Lemarié, C. A., & Schiffrin, E. L. (2010). The angiotensin II type 2 receptor in cardiovascular disease. Journal of the Renin-Angiotensin-Aldosterone System. https://doi.org/10.1177/1470320309347785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.